Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.

The pharmacogenomics journal - 1 Jan 2017

Franca R, Rebora P, Bertorello N, Fagioli F, Conter V, Biondi A, Colombini A, Micalizzi C, Zecca M, Parasole R, Petruzziello F, Basso G, Putti M C, Locatelli F, d'Adamo P, Valsecchi M G, Decorti G, Rabusin M

Abstract excerpt

Drug-related toxicities represent an important clinical concern in chemotherapy, genetic variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was performed on 508 pediatric acute lymphoblastic leukemia patients treated with AIEOP-BFM 2000 protocol: 28 variants were genotyped by VeraCode and Taqman technologies, deletions of GST-M1 and GST-T1 by multiplex PCR. Toxicities were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemical and Drug Induced Liver Injury
Share to Gastrointestinal Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Induction Chemotherapy

Share to Multidrug Resistance-Associated Proteins

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Pyrophosphatases

Share to Receptor, Adenosine A2A

Source

Identifiers

PMID: 26644204
DOI: 10.1038/tpj.2015.83

Genes

ABCC1
ITPA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.PMID 26644204Read ↗

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.Semantic proximity Read ↗

Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina.Semantic proximity Read ↗

Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL Study GroupSemantic proximity Read ↗

Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia.Semantic proximity Read ↗

Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review)Semantic proximity Read ↗

Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.Semantic proximity Read ↗

Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.Semantic proximity Read ↗

Ancestry and pharmacogenetics of antileukemic drug toxicity.Semantic proximity Read ↗

Genetic variants associated with oral mucositis in pediatric patients with acute lymphoblastic leukemia and lymphoma undergoing chemotherapy.Semantic proximity Read ↗

Pharmacogenetic aspects of efficacy and safety of methotrexate treatment in pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.